Protein kinase C inhibitors
AssigneeEli Lilly and Company
InventorsWilliam F. Heath, Jr., Michael R. Jirousek, John H. McDonald, III, Christopher J. Rito
Life of this patent
Estimating the term…
Abstract
This invention provides novel bis-indolemaleimide macrocycle derivatives of the formula: ##STR1## The invention further provides the preparation, pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.
Claims7
A method for treating restenosis comprising administering a therapeutically effective amount of a PKC inhibitor.
A method of treating restenosis following revascularization comprising administering a therapeutically effective amount of a PKC inhibitor for a time sufficient to prevent restenosis.
A method of treating restenosis following revascularization comprising the local delivery of a PKC inhibitor.
A method of preventing smooth muscle cell proliferation in a patient and need thereof comprising administering a PKC inhibitor.
A method of preventing smooth muscle cell proliferation in a patient and need thereof comprising administering locally an effective therapeutic amount of a PKC inhibitor.
Use of a PKC inhibitor for the preparation of a medicament for the treatment of restenosis.
Dependencies are inferred from the claim text.